Camilla Suzanne Graham, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 12 | 2020 | 1579 | 1.540 |
Why?
|
| Hepacivirus | 11 | 2020 | 1330 | 1.360 |
Why?
|
| Hepatitis C, Chronic | 8 | 2017 | 1027 | 1.060 |
Why?
|
| Antiviral Agents | 6 | 2016 | 3048 | 0.620 |
Why?
|
| Ribavirin | 3 | 2015 | 394 | 0.490 |
Why?
|
| Macrocyclic Compounds | 1 | 2015 | 68 | 0.480 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 66 | 0.470 |
Why?
|
| Fluorenes | 1 | 2015 | 157 | 0.450 |
Why?
|
| Uracil | 1 | 2015 | 207 | 0.440 |
Why?
|
| Carbamates | 1 | 2015 | 191 | 0.430 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 494 | 0.430 |
Why?
|
| Ritonavir | 1 | 2015 | 329 | 0.420 |
Why?
|
| Anilides | 1 | 2015 | 411 | 0.390 |
Why?
|
| Benzimidazoles | 1 | 2015 | 858 | 0.330 |
Why?
|
| HIV Infections | 8 | 2015 | 17348 | 0.250 |
Why?
|
| Hepatitis C Antigens | 1 | 2005 | 34 | 0.250 |
Why?
|
| Sulfonamides | 1 | 2015 | 1977 | 0.240 |
Why?
|
| Mass Screening | 3 | 2020 | 5426 | 0.200 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 529 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2005 | 4373 | 0.160 |
Why?
|
| Liver | 4 | 2005 | 7512 | 0.140 |
Why?
|
| Interleukin-10 | 3 | 2007 | 1176 | 0.130 |
Why?
|
| HIV | 1 | 2003 | 1581 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 2196 | 0.130 |
Why?
|
| 2-Naphthylamine | 1 | 2015 | 20 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 4027 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2015 | 123 | 0.110 |
Why?
|
| Cyclopropanes | 1 | 2015 | 432 | 0.110 |
Why?
|
| Interferon-gamma | 6 | 2007 | 3155 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 408 | 0.110 |
Why?
|
| Proline | 1 | 2015 | 455 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 1 | 2015 | 318 | 0.110 |
Why?
|
| Interferon-alpha | 3 | 2006 | 907 | 0.100 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 745 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2017 | 703 | 0.100 |
Why?
|
| Polyethylene Glycols | 3 | 2006 | 1187 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 602 | 0.080 |
Why?
|
| HIV-1 | 2 | 2007 | 6851 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1662 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 5426 | 0.070 |
Why?
|
| Drug Costs | 1 | 2015 | 1183 | 0.070 |
Why?
|
| Heroin Dependence | 1 | 2007 | 172 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2005 | 1895 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2008 | 503 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 147 | 0.060 |
Why?
|
| Candida | 1 | 2005 | 172 | 0.060 |
Why?
|
| Piperacillin | 1 | 2003 | 37 | 0.050 |
Why?
|
| Enterobacter | 1 | 2003 | 44 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2003 | 57 | 0.050 |
Why?
|
| Schistosomiasis mansoni | 1 | 2004 | 94 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2003 | 41 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 575 | 0.050 |
Why?
|
| Humans | 21 | 2020 | 761222 | 0.050 |
Why?
|
| Schistosoma mansoni | 1 | 2004 | 156 | 0.050 |
Why?
|
| Poverty | 1 | 2015 | 2691 | 0.050 |
Why?
|
| Medicaid | 1 | 2016 | 2813 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2004 | 227 | 0.050 |
Why?
|
| Developing Countries | 1 | 2015 | 2863 | 0.050 |
Why?
|
| Ceftriaxone | 1 | 2003 | 175 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 4574 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2006 | 6504 | 0.050 |
Why?
|
| Morbidity | 1 | 2007 | 1751 | 0.050 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2003 | 187 | 0.050 |
Why?
|
| Adult | 13 | 2016 | 221120 | 0.040 |
Why?
|
| Middle Aged | 12 | 2016 | 220858 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2006 | 1553 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3803 | 0.040 |
Why?
|
| Male | 15 | 2016 | 360703 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 1963 | 0.040 |
Why?
|
| United States | 3 | 2017 | 72341 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2005 | 1361 | 0.040 |
Why?
|
| Anti-HIV Agents | 2 | 2005 | 4527 | 0.040 |
Why?
|
| Fibrosis | 1 | 2005 | 2052 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 1783 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2005 | 12052 | 0.030 |
Why?
|
| Alcoholism | 1 | 2007 | 1973 | 0.030 |
Why?
|
| Viral Load | 1 | 2005 | 3328 | 0.030 |
Why?
|
| Female | 14 | 2016 | 392552 | 0.030 |
Why?
|
| Age Factors | 1 | 2012 | 18384 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6819 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7400 | 0.030 |
Why?
|
| Monocytes | 1 | 2004 | 2570 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 623 | 0.030 |
Why?
|
| Immunoassay | 1 | 2017 | 743 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 1932 | 0.030 |
Why?
|
| Cytokines | 2 | 2006 | 7386 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 741 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2006 | 12747 | 0.020 |
Why?
|
| Mortality | 1 | 2003 | 2896 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 4413 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2016 | 41496 | 0.020 |
Why?
|
| Antibodies | 1 | 2017 | 2415 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2017 | 2839 | 0.020 |
Why?
|
| Adolescent | 2 | 2006 | 88300 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 74241 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 169292 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10203 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 59222 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2008 | 64681 | 0.020 |
Why?
|
| Inflammation | 1 | 2005 | 10759 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6304 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7407 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2006 | 390 | 0.010 |
Why?
|
| Acute Disease | 2 | 2004 | 7226 | 0.010 |
Why?
|
| beta-Lactam Resistance | 1 | 2003 | 73 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 13367 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2006 | 1042 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2006 | 1071 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4567 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2854 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 14610 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2008 | 54437 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 6312 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 4451 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2004 | 2189 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 5478 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 10516 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2016 | 80675 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 6781 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 9319 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 18927 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 12474 | 0.000 |
Why?
|
| Disease Progression | 1 | 2004 | 13511 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 26072 | 0.000 |
Why?
|
| Animals | 1 | 2004 | 168089 | 0.000 |
Why?
|